Plasma fractionation in China: progress and challenges

China is one of the largest consumers and manufacturers in the global plasma-derived products market and serves a huge population of more than 1.3 billion. Both blood and plasma-derived products are regarded as strategic resources in China. Great progress has been made in the Chinese plasma fractionation industry in the past 50 years, while problems still remain. Self-sufficiency and strategic independence of plasma-derived products has not yet been achieved. Reviews of Chinese plasma fractionation have seldom been published. The Chinese experiences with plasma fractionation may, however, lend lessons to other developing countries, especially countries along the Belt and Road routes, as well as contribute to global improvements on plasma fractionation.